265 related articles for article (PubMed ID: 26268594)
1. LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5.
Shanley MR; Hawley D; Leung S; Zaidi NF; Dave R; Schlosser KA; Bandopadhyay R; Gerber SA; Liu M
Biochemistry; 2015 Aug; 54(33):5198-208. PubMed ID: 26268594
[TBL] [Abstract][Full Text] [Related]
2. Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity.
Shu Y; Ming J; Zhang P; Wang Q; Jiao F; Tian B
PLoS One; 2016; 11(3):e0149739. PubMed ID: 26930193
[TBL] [Abstract][Full Text] [Related]
3. Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Hamm M; Bailey R; Shaw G; Yen SH; Lewis J; Giasson BI
J Neurosci Res; 2015 Oct; 93(10):1567-80. PubMed ID: 26123245
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β.
Kawakami F; Shimada N; Ohta E; Kagiya G; Kawashima R; Maekawa T; Maruyama H; Ichikawa T
FEBS J; 2014 Jan; 281(1):3-13. PubMed ID: 24165324
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth.
Kawakami F; Yabata T; Ohta E; Maekawa T; Shimada N; Suzuki M; Maruyama H; Ichikawa T; Obata F
PLoS One; 2012; 7(1):e30834. PubMed ID: 22303461
[TBL] [Abstract][Full Text] [Related]
6. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
Gillardon F
J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
[TBL] [Abstract][Full Text] [Related]
7. Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression.
Ho DH; Kim H; Kim J; Sim H; Ahn H; Kim J; Seo H; Chung KC; Park BJ; Son I; Seol W
Mol Brain; 2015 Sep; 8():54. PubMed ID: 26384650
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
9. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
Nguyen APT; Daniel G; Valdés P; Islam MS; Schneider BL; Moore DJ
Hum Mol Genet; 2018 Jan; 27(1):120-134. PubMed ID: 29088368
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
West AB; Moore DJ; Biskup S; Bugayenko A; Smith WW; Ross CA; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 2005 Nov; 102(46):16842-7. PubMed ID: 16269541
[TBL] [Abstract][Full Text] [Related]
11. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
Qing H; Wong W; McGeer EG; McGeer PL
Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 I2020T mutation is associated with tau pathology.
Ujiie S; Hatano T; Kubo S; Imai S; Sato S; Uchihara T; Yagishita S; Hasegawa K; Kowa H; Sakai F; Hattori N
Parkinsonism Relat Disord; 2012 Aug; 18(7):819-23. PubMed ID: 22525366
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
[TBL] [Abstract][Full Text] [Related]
15. Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substrate.
Krumova P; Reyniers L; Meyer M; Lobbestael E; Stauffer D; Gerrits B; Muller L; Hoving S; Kaupmann K; Voshol J; Fabbro D; Bauer A; Rovelli G; Taymans JM; Bouwmeester T; Baekelandt V
FASEB J; 2015 Jul; 29(7):2980-92. PubMed ID: 25854701
[TBL] [Abstract][Full Text] [Related]
16. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
[TBL] [Abstract][Full Text] [Related]
17. Dominant-negative effects of LRRK2 heterodimers: a possible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation.
Ohta E; Kawakami F; Kubo M; Obata F
Biochem Biophys Res Commun; 2013 Jan; 430(2):560-6. PubMed ID: 23220480
[TBL] [Abstract][Full Text] [Related]
18. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
19. I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway.
Ohta E; Nihira T; Uchino A; Imaizumi Y; Okada Y; Akamatsu W; Takahashi K; Hayakawa H; Nagai M; Ohyama M; Ryo M; Ogino M; Murayama S; Takashima A; Nishiyama K; Mizuno Y; Mochizuki H; Obata F; Okano H
Hum Mol Genet; 2015 Sep; 24(17):4879-900. PubMed ID: 26056228
[TBL] [Abstract][Full Text] [Related]
20. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.
Smith WW; Pei Z; Jiang H; Moore DJ; Liang Y; West AB; Dawson VL; Dawson TM; Ross CA
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18676-81. PubMed ID: 16352719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
